Skip to main content

Advertisement

Table 2 Adverse events during the pirfenidone and nintedanib administration periods

From: Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis

  During the pirfenidone administration period (n = 30) During the nintedanib administration period (n = 30)
Subjects CTCAE grade Subjects CTCAE grade
1 2 3 1 2 3
Gastrointestinal
 Anorexia 19 (63.3%) 3 14 2 14 (46.7%) 3 8 3
 Weight loss 17 (56.7%) 10 5 2 6 (20.0%) 3 3 0
 Diarrhea 0 0 0 0 14 (46.7%) 6 7 1
 Dyspepsia 5 (16.7%) 1 4 0 0 0 0 0
 Nausea 0 0 0 0 2 (6.7%) 0 2 0
 Vomiting 0 0 0 0 2 (6.7%) 2 0 0
Other
 AST/ALT elevation 1 (3.3%) 0 0 1 19 (63.3%) 12 5 2
 Fatigue 5 (16.7%) 1 4 0 3 (10.0%) 1 1 1
 Photosensitivity 3 (10.0%) 2 0 1 0 0 0 0
 Rash 2 (6.7%) 2 0 0 0 0 0 0
 Abdominal pain 0 0 0 0 3 (10.0%) 2 1 0
 Back pain 2 (6.7%) 0 2 0 0 0 0 0
 Non-cardiac chest pain 1 (3.3%) 1 0 0 0 0 0 0
 Fever 0 0 0 0 2 (6.7%) 2 0 0
 Acute exacerbation 0 0 0 0 2 (6.7%) 0 0 2
  1. Categorical data are presented as numbers (percentages)
  2. Abbreviations: AST aspartate aminotransferase, ALT alanine aminotransferase, CTCAE Common Terminology Criteria for Adverse Events